Lysergide Treatment of Schizophrenic and Nonschizophrenic Alcoholics; A Controlled Evaluation

Single Oral Lysergide (LSD 500 µg) in Inpatient Alcoholic Rehabilitation: Controlled Evaluation with Schizophrenic Sub-Analysis (Tomsovic & Edwards 1970)

Controlled evaluation of single oral lysergide (LSD) 500 µg in an inpatient 90-day Alcoholic Rehabilitation Programme (Q J Stud Alcohol 1970 Dec; Tomsovic M, Edwards RV; PMID 5490826). n=75 volunteers received lysergide; among these, 23 were classified as schizophrenic. Volunteers paired with contemporaneous admissions; at day 45, one of each pair assigned to lysergide by coin toss (partially randomised). Control group I: volunteers who did not receive lysergide or received placebo substitute. Control group II: routine programme participants who had completed before the project or did not volunteer. Session: single oral 500 µg lysergide in specially furnished room (colourful drapes, pictures, music); patient-chosen nursing assistant present non-directively for 7 h; administering psychiatrist made intermittent visits; preparatory readings and debrief the next day. Primary outcome: drinking control (Drinking Adjustment Scale) at 3, 6, and 12 months; validation by spouses/informants. Secondary: Blewett & Chwelos Scales (acute/subacute reactions); subjective session classification ("good"/"moderate"/"poor"); rates of recrudescence (vivid post-session recurrences). Schizophrenic vs non-schizophrenic sub-analyses. No registration (pre-registration era, 1970). CT.gov: 0 hits.

Started

January 1, 1966

Type

interventional

Blinding

single

Randomized

Yes

Registry ID

TOMSOVIC-1970-QJSTUDIALCOHOL-LYSERGIDE-ALCOHOLICS